1. Home
  2. SLNO vs QTWO Comparison

SLNO vs QTWO Comparison

Compare SLNO & QTWO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLNO
  • QTWO
  • Stock Information
  • Founded
  • SLNO 1999
  • QTWO 2004
  • Country
  • SLNO United States
  • QTWO United States
  • Employees
  • SLNO N/A
  • QTWO N/A
  • Industry
  • SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • QTWO Computer Software: Prepackaged Software
  • Sector
  • SLNO Health Care
  • QTWO Technology
  • Exchange
  • SLNO Nasdaq
  • QTWO Nasdaq
  • Market Cap
  • SLNO 3.8B
  • QTWO 4.5B
  • IPO Year
  • SLNO 2014
  • QTWO 2014
  • Fundamental
  • Price
  • SLNO $82.17
  • QTWO $92.66
  • Analyst Decision
  • SLNO Strong Buy
  • QTWO Buy
  • Analyst Count
  • SLNO 9
  • QTWO 17
  • Target Price
  • SLNO $103.33
  • QTWO $102.81
  • AVG Volume (30 Days)
  • SLNO 1.0M
  • QTWO 525.5K
  • Earning Date
  • SLNO 08-06-2025
  • QTWO 07-30-2025
  • Dividend Yield
  • SLNO N/A
  • QTWO N/A
  • EPS Growth
  • SLNO N/A
  • QTWO N/A
  • EPS
  • SLNO N/A
  • QTWO N/A
  • Revenue
  • SLNO N/A
  • QTWO $720,691,000.00
  • Revenue This Year
  • SLNO N/A
  • QTWO $14.34
  • Revenue Next Year
  • SLNO N/A
  • QTWO $10.53
  • P/E Ratio
  • SLNO N/A
  • QTWO N/A
  • Revenue Growth
  • SLNO N/A
  • QTWO 13.12
  • 52 Week Low
  • SLNO $39.41
  • QTWO $59.51
  • 52 Week High
  • SLNO $86.79
  • QTWO $112.82
  • Technical
  • Relative Strength Index (RSI)
  • SLNO 59.70
  • QTWO 58.86
  • Support Level
  • SLNO $82.41
  • QTWO $92.25
  • Resistance Level
  • SLNO $86.79
  • QTWO $95.17
  • Average True Range (ATR)
  • SLNO 2.94
  • QTWO 2.54
  • MACD
  • SLNO 0.17
  • QTWO 0.28
  • Stochastic Oscillator
  • SLNO 60.94
  • QTWO 71.28

About SLNO Soleno Therapeutics Inc.

Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.

About QTWO Q2 Holdings Inc.

Q2 Holdings Inc. is a provider of cloud-based virtual banking solutions for regional financial institutions to deliver mobile banking services to retail and commercial end-users who wish to bank anywhere and anytime. Its solutions operate on an integrated tablet-first platform which provides financial institutions a comprehensive view of account holder activity and meets the regulatory and security requirements applicable to the industry. The firm generates revenue from subscription-based arrangements for software offerings. A large majority of the firm's revenue is generated in the United States.

Share on Social Networks: